Loading...
XKRX
003090
Market cap475mUSD
Jul 10, Last price  
17,030.00KRW
1D
0.00%
1Q
-23.97%
Jan 2017
93.30%
Name

Daewoong Co Ltd

Chart & Performance

D1W1MN
XKRX:003090 chart
P/E
4.09
P/S
0.35
EPS
4,164.51
Div Yield, %
1.17%
Shrs. gr., 5y
6.73%
Rev. gr., 5y
8.82%
Revenues
2.07t
+6.80%
500,880,459,000607,247,194,000695,010,620,000766,644,083,000670,825,226,000270,641,226,890306,154,896,540843,534,264,430893,976,778,700996,645,900,6501,015,010,730,4701,124,075,727,1401,231,173,935,6601,365,679,369,3301,355,337,387,0001,511,373,581,0001,697,338,483,0001,815,103,675,0001,936,916,853,0002,068,631,012,000
Net income
175.06b
+202.43%
24,284,888,00029,629,972,00015,878,328,00020,011,814,00032,363,158,00043,268,255,00044,199,500,18040,771,653,96023,811,158,08038,623,412,96019,831,075,11066,250,630,10029,863,274,89062,439,349,48098,378,893,00078,730,195,000102,565,589,000152,665,122,00057,885,500,000175,062,903,000
CFO
257.58b
+58.62%
52,235,463,00041,661,606,00056,712,968,000118,036,604,00034,417,099,00010,404,679,58027,615,344,38086,193,904,77046,607,316,99074,916,093,23018,755,841,540147,774,279,09045,380,803,380138,512,224,900145,365,813,000133,175,353,000149,081,681,000205,654,598,000162,384,531,000257,576,923,000
Dividend
Dec 29, 2025200 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Operating alongside its various subsidiaries, Daewoong Co., Ltd. is primarily engaged in the production and sale of pharmaceutical products. Additionally, the company generates income from real estate leasing. Established in 1961, the firm transitioned its name from Daewoong Pharmaceutical Co., Ltd. to its current designation, Daewoong Co., Ltd., in 2002. Its corporate headquarters are located in Seongnam-si, South Korea.
URL
http://www.daewoongholdings.com/
IPO date
Jun 26, 1973
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT